The FDA granted orphan designation to Merck’s recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor as a treatment of gastric cancer, including cancer of the gastroesophageal junction, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- FDA Approves Merck’s (MRK) New Vaccine, Capvaxive
- FDA approves pembro plus chemo for endometrial carcinoma
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 6/7/2024
- Coherus Biosciences appoints Karachun to board of directors